What are Sodium channel blocker drugs?

Sodium channel blocker drugs are pharmacologic agents that share a common mechanism (typically targeting Nav1.5). 1 are currently marketed, with 5 more in clinical development.

What are the marketed Sodium channel blocker drugs?

Marketed Sodium channel blocker drugs include Medium-dose anrikefon.

Sodium channel blocker

1 marketed 3 in Phase 3 2 in Phase 2

This page covers all Sodium channel blocker drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Nav1.5, cardiac sodium channel, Nav1.7.

Targets

Nav1.5 · cardiac sodium channel · Nav1.7 · Voltage-gated sodium channels · voltage-gated sodium channels · Nav1.8

Marketed (1)

Medium-dose anrikefon · Peking University First Hospital · Cardiovascular
Anrikefon is a selective inhibitor of the sodium channel Nav1.5, which helps to regulate the heart's rhythm.

Phase 3 pipeline (3)

SVT-15652 · Salvat · Cardiovascular
SVT-15652 is a small molecule that targets the cardiac sodium channel.
XEN1101 · Xenon Pharmaceuticals Inc. · Pain
XEN1101 is a selective Nav1.7 sodium channel blocker.
XP13512 (GSK1838262) · XenoPort, Inc. · Neurology
XP13512 is a voltage-gated sodium channel blocker.

Phase 2 pipeline (2)

Eslicarbazepine Acetate tablets · Eisai Inc. · Neurology
Eslicarbazepine acetate is a voltage-gated sodium channel blocker that stabilizes neuronal membranes and suppresses post-tetanic potentiation.
AN2690 Solution, 7.5% · Pfizer · Pain
AN2690 Solution, 7.5% is a drug that works by inhibiting the activity of the sodium channel Nav1.8.